Tech Company Financing Transactions
NewLeaf Symbiotics Funding Round
On 12/19/2023, NewLeaf Symbiotics raised $45 million in Series D funding from Gullspang Refood, Leaps by Bayer and Otter Capital.
Transaction Overview
Company Name
Announced On
12/19/2023
Transaction Type
Venture Equity
Amount
$45,000,000
Round
Series D
Investors
Proceeds Purpose
With this funding, NewLeaf will accelerate its efforts with PPFM technology and adjacent technologies in the areas of biostimulants/microbial inoculants, biocontrol, nitrogen use efficiency and methane mitigation.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1005 North Warson Rd.
St. Louis, MO 63132
USA
St. Louis, MO 63132
USA
Phone
Website
Email Address
Overview
NewLeaf Symbiotics is a science-based company doing cutting-edge research and product development, using a naturally occurring family of beneficial plant bacteria.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Stephen Kahn
Chief Scientific Officer
Desmond Jimenez
Chief Technical Officer
Janne Kerovuo
VP - Bus. Development
Matthew Helms
VP - General Counsel
Molly Edwards
VP - Manufacturing
Aaron Kelley
VP - R & D
Natalie Breakfield
Browse more venture capital transactions:
Prev: 12/19/2023: Kimia Therapeutics venture capital transaction
Next: 12/19/2023: GTA venture capital transaction
Share this article
News on VC Transactions
We do our best to document tech company VC transactions. All VC database entries reported here are sourced from publicly available VC deal announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs